Investing.com - Biogen (NASDAQ:BIIB) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biogen announced earnings per share of $3.39 on revenue of $2.73B. Analysts polled by Investing.com anticipated EPS of $3.35 on revenue of $2.62B.
Biogen shares are down 6% from the beginning of the year, still down 51.95% from its 52 week high of $468.20 set on June 7, 2021. They are under-performing the S&P 500 which is down 3.71% from the start of the year.
Biogen follows other major Healthcare sector earnings this month
Biogen's report follows an earnings beat by J&J on January 25, who reported EPS of $2.13 on revenue of $24.8B, compared to forecasts EPS of $2.12 on revenue of $25.28B.
UnitedHealth had beat expectations on January 19 with fourth quarter EPS of $4.48 on revenue of $73.74B, compared to forecast for EPS of $4.3 on revenue of $72.98B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar